MeCure's Strong Q1 Performance Masks Persistent Tax Challenges in Nigeria's Pharma Sector

MeCure Industries Plc delivered a strong financial performance in first quarter (Q1) 2026, navigating a still-challenging but gradually stabilizing macroeconomic environment in Nigeria and globally. For a tax analyst, this headline is a distraction from the real story: Nigeria's tax authority is losing the war against the informal pharmaceutical sector.

Tax amnesty misses the informal market

Nigeria's pharmaceutical market is substantial, according to industry research. The same sources project significant expansion over the coming years. That is real growth. But how much of it is taxable?

The informal segment—patent medicine vendors, roadside dispensaries, unregistered wholesalers—likely handles a large chunk of the market. Nigeria's tax amnesty programs have focused on formal companies like MeCure. The informal players keep operating in cash, outside VAT and corporate income tax nets. The risk is that the revenue growth comes mostly from the already-taxed formal sector, while the tax base stays flat.

Suppose the government wants to widen the base. It needs FIRS to spend less time auditing listed companies and more time tracking informal supply chains. So far, the agency has shown little capacity for that.

Compliance costs eat into growth

For listed firms like MeCure, tax compliance is expensive. Multiple tax remittances, VAT returns, withholding tax filings—all require dedicated staff and consultants. The informal competitors pay none of that. This creates a structural disadvantage for MeCure and other formal players.

The strong revenue growth is impressive, but the effective tax rate may rise as FIRS tightens enforcement on the formal sector. Expect MeCure's tax expense to grow faster than revenue in the coming quarters. That will pressure net margins.

I keep coming back to a simple point: if the informal sector remains untaxed, the government will keep squeezing the formal one. That is not sustainable. The market growth projected by analysts will mostly accrue to informal players unless FIRS changes tactics.

What investors should watch

Investors should watch three things. First, FIRS's quarterly collection numbers for the pharmaceutical sector. If formal sector tax payments rise sharply, the informal share is either shrinking or being brought into the net. Second, any new amnesty program with teeth—not just the usual voluntary disclosure with low penalties. Third, MeCure's own tax provisions as a share of revenue.

The broader risk is that Nigeria's tax-to-GDP ratio remains low despite headline growth in sectors like pharma. That means the government will keep borrowing or printing money, both of which hurt the naira and inflation outlook. For foreign investors eyeing MeCure's stock, the currency risk is the real tax.

The Q1 report is a good story. But the tax hole underneath it is the one that matters.